THERANOSTICS 润色咨询

Theranostics

出版年份：2011 年文章数：3138 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：7.7% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2018-12-28 124bde92m63暂无昵称

    请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2024-06-18 ms2000001347401459 来自湖南省

    请问大家，注册是需要机构邮箱吗

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2024-06-08 ms7000000383229757 来自广西

    期刊要求使用学校邮箱 怎样注册啊

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-04-26 ms7000000635207998

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤
    经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。

    23

    展开23条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2023-12-26 ms7000000485286504 来自四川省

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2024-05-29 ms2000000210233780 来自重庆

    请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2024-01-10 ms1000000959787142 来自四川省

    感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗

    8

    展开8条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2023-11-07 ILGN 来自广东省

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：要求很高了

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2023-03-14 Judy Bright 来自安徽省

    偏重的研究方向：肺癌;药物治疗
    经验分享：向有投稿经验的人请教一下。
    请问大家这个期刊投稿会显示每一步的投稿状态吗？
    文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？
    而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？

    6

    展开6条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=564969, encodeId=19775649699b, content=请问一定要用通讯作者的邮箱投么？一时没注意用了一作的邮箱投了怎么办？急，在线等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccab2511503, createdName=124bde92m63暂无昵称, createdTime=Fri Dec 28 00:00:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210580, encodeId=6bbc2210580f1, content=请问大家，注册是需要机构邮箱吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca9337250, createdName=ms2000001347401459, createdTime=Tue Jun 18 22:22:51 CST 2024, time=2024-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2208953, encodeId=6f072208953fe, content=期刊要求使用学校邮箱 怎样注册啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9e98252801, createdName=ms7000000383229757, createdTime=Sat Jun 08 16:29:24 CST 2024, time=2024-06-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2207284, encodeId=94d6220e2847f, content=请问现在这个杂志怎么样呀，自己的第一篇通讯文章，想试试10分左右的肿瘤，实在是太纠结了，不知道往哪里投比较好呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=56985490010, createdName=ms2000000210233780, createdTime=Wed May 29 16:25:34 CST 2024, time=2024-05-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-09-11 1811e984f8m

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：分子生物
    经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。

    10

    展开10条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分